ÂÜÀòÂÒÂ×

Julie Rousseau has an extensive work experience in the field of biology and oncology. Julie is currently serving as the Associate Director of Translational Biology at Alpha-9 Theranostics Inc. since January 2023. Prior to that, they worked as a Senior Scientist at the same company from September 2021 to December 2022.

Before joining Alpha-9 Theranostics Inc., Julie worked at BC Cancer, where they held multiple positions. Julie was a Research Associate in Dr. Francois Benard's lab in the Molecular Oncology Department from November 2019 to September 2021. Prior to that, they worked as a Post-doctoral fellow in F. Benard's group in the Molecular Oncology Department from September 2015 to November 2019.

Julie also gained experience as a Post-doctoral fellow at Ecole nationale vétérinaire de Nantes from November 2010 to August 2015. Additionally, they worked as an Animal Physiology Teacher at ESAV Institut Bonaparte from October 2011 to June 2014.

Julie's earlier experiences include roles as a PhD student and an Interface contract (Doctorant-conseil) at Inserm from October 2007 to October 2010 and September 2009 to August 2010, respectively. Julie also worked as a Master 2 student and an Assistant Engineer at Inserm and Pfizer, respectively.

Overall, Julie Rousseau has gained a diverse range of experiences in research, teaching, and industry settings, demonstrating their expertise in various aspects of biology and oncology.

Julie Rousseau obtained their first degree from Nantes Université, where they completed a Master's in Cellular Biology, Physiology, Biotechnologies, and Therapeutic Research from 2005 to 2007. Following this, they pursued a PhD in Molecular and Cellular Aspects of Biology at the same institution from 2007 to 2010.